STOCKHOLM, Aug. 24, 2018 /PRNewswire/ -- "On 3 April,
trading in Immunovia's shares started on NASDAQ Stockholm's main
market, where we are listed in the Mid Cap segment. During the
second quarter we also completed a directed share issue worth
around SEK 324 million to reputable
institutions in Sweden and
internationally.
Very exciting results have been achieved in two major
application areas, lung cancer and rheumatoid arthritis, which show
that the general usability of the IMMray™ platform opens up great
opportunities for Immunovia.
During the spring and summer we completed a lung cancer study
with very good results. This was our first collaboration with a
global, top-ten pharmaceutical business and the aim was to assess
the technical performance of the IMMray™ platform within lung
cancer.
In the autoimmune field we have made significant progress within
rheumatoid arthritis. In August we published results that mean we
will now continue our efforts aimed at developing a product for
patients that are difficult to diagnose in this area.
The main focus, as usual, was on IMMray™ PanCan-d. Work has
proceeded according to plan in the second quarter. In August,
however, new data emerged showing that the sample-collection
procedure, which will be applicable commercially and for our final
validation studies, affects our product's algorithms. We have
therefore decided that a necessary stage is to optimize IMMray™
PanCan-d to safeguard the quality of the test results prior to
release. This will delay the start of sales to the latter part of
2019," said Mats Grahn, CEO of
Immunovia AB.
Key Indicators
Key
Indicators
(SEK thousand
unless otherwise stated)
|
1
Apr- 30 June 2018
|
1
Apr- 30 June 2017
|
1
Jan- 30 June 2018
|
1
Jan- 30 June 2017
|
Full year
2017
|
Net sales
|
44
|
68
|
156
|
95
|
149
|
Operating
earnings
|
–27,232
|
–10,645
|
–44,608
|
–18,515
|
-45,520
|
Earnings before
tax
|
–26,147
|
–10,554
|
–43,473
|
–18,325
|
-45,232
|
Net
earnings
|
–26,154
|
–10,554
|
–43,480
|
–18,325
|
-45,232
|
Earnings per share
before and after dilution (SEK/share)
|
–1.47
|
–0.63
|
–2.47
|
–1.09
|
-2.67
|
|
Equity ratio,
%
|
96
|
96
|
96
|
96
|
94
|
No. of shares at the
end of the period
|
19,480,853
|
16,804,059
|
19,480,853
|
16,804,059
|
17,318,059
|
Average no. of shares
before and after dilution
|
17,846,742
|
16,804,059
|
17,582,400
|
16,804,059
|
16,932,559
|
This financial statement has been produced in accordance with
IFRS for the Immunovia Group, which comprises Immunovia AB and the
wholly-owned subsidiaries Immunovia Inc. and Immunovia
GmbH.
Outlook
Immunovia is focused on fundamentally transforming diagnosis of
complex forms of cancer and autoimmune diseases. The antibody-based
platform, IMMray™, is the result of 15 years of research at CREATE
Health – the Center for Translational Cancer Research at
Lund University, Sweden. IMMray™ is a technology platform for
the development of diagnostic tests and the company's primary test,
IMMray™ PanCan-d, is the first test in the world for early
diagnosis of pancreatic cancer.
The company's financial targets remain in place, but have been
delayed in relation to previous announcements, due to the need to
perform optimization studies. The company expects to receive the
first revenues from self-pay sales in the latter part of 2019.
The following financial targets have been established:
• Immunovia's target is to achieve turnover of SEK 250-300 million by 2022 based on self-pay for
IMMray™ PanCan-d.
• Immunovia's target is to achieve total turnover, including
payment via self-pay and cost remuneration from insurance systems,
of SEK 800-1,000 million by 2024.
This information is information that Immunovia AB (publ) is
obliged to make public pursuant to the EU Market Abuse Regulation.
The information was submitted for publication on 24 August at CET
08:30, through the agency of the contact person set out
above.
For further information, please contact:
Mats Grahn, CEO, Immunovia AB
Phone: +46(0)70-532-02-30
E-mail: mats.grahn@immunovia.com
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases
diagnosis, prognosis and therapy monitoring.
(Source: www.immunovia.com)
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-interim-report--january-june-2018,c2599690
The following files are available for download:
http://mb.cision.com/Main/13121/2599690/896521.pdf
|
PDF
|